Representatives from Kidney Research UK conducted a site visit to Bournemouth on Monday hosted by the Department of Life and Environmental Science (Dr. Paul Hartley and Shruthi Sivakumar) as well as Prof. John Fletcher. The event was attended by clinician-researchers from Bristol and Brighton Universities and was intended as a ‘meet and greet’ between the charity and its funded researchers. The day was highly productive and KRUK’s representatives were very impressed by BU’s research labs, projects and learning environment (especially the spanking new Leica SP8 confocal microscope).
BU currently holds an Innovation Award from KRUK for the use of fruit flies to study the genetics of kidney failure in diabetes. This work is important because kidney disease is a common condition and major contributing factor to cardiovascular disease worldwide. Astonishingly, there are still very few treatments beyond dialysis and a very poor life expectancy (3 years) when diagnosed with kidney disease in your 40’s.
The charity stressed that they are highly receptive to new applications that tackle this problem. Funding is not restricted to basic science or clinical research…so if you have any good ideas…let them know and get an application started!!
http://www.kidneyresearchuk.org/research
An informative powerpoint by KRUK is available as pdf format – let me know if you’re interested in having a copy (phartley@bournemouth.ac.uk)
Strong Presence of BU at UK Kidney Week










Fourth INRC Symposium: From Clinical Applications to Neuro-Inspired Computation
Writing policy briefs
Upholding Excellence: The Concordat to Support Research Integrity
Today’s Documentation Will Serve Tomorrow’s Justice
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Horizon Europe Work Programme 2025 Published
Horizon Europe 2025 Work Programme pre-Published
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease